

January 31, 2022

To The Manager, Listing Department National Stock Exchange of India Limited Plot no. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai- 400 051 Symbol: BLISSGVS	To The General Manager, Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 506197
---	--

Dear Sir/Madam,

Subject: Newspaper Publication of Unaudited Financial Results for the quarter and nine months ended December 31, 2021

Pursuant to the provision of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the extract copies of newspaper advertisement of Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2021 published in 'The Economic Times & The Free Press Journal' an English Daily and 'Maharashtra Times & Navshkati' a Regional Daily, on January 31, 2022.

Kindly take the same on record.

Thanking you.

Yours faithfully,
For **Bliss GVS Pharma Limited**


Aditi Bhatt
Company Secretary



Encl: as above

Regd. Office : 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

TEL. : (+91) (22) 42160000/ 28505387 • FAX. : (+91) (22) 28563930,

Email : info@blissgvs.com • Website : www.blissgvs.com • CIN - L24230MH1984PLC034771

Factory : Plot No. 10, 11 & 12, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404.
Tel. (+91) (02525) 252713 • Fax : (+91) (02525) 255257. • Email : factory@blissgvs.com



BLISS GVS PHARMA LIMITED

CIN No.- L24230MH1984PLC034771

Registered Office: 102, Hyde Park, Sakinaka Road, Andheri (East), Mumbai - 400 072.

• Tel: 022-42160000 • Fax: 022-28563930 • Email: info@blissgvs.com • Website: www.blissgvs.com

EXTRACT OF STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2021

(₹ in Lakhs)

Particulars	STANDALONE					CONSOLIDATED				
	QUARTER ENDED		NINE MONTHS ENDED		YEAR ENDED	QUARTER ENDED		NINE MONTHS ENDED		YEAR ENDED
	31.12.2021	31.12.2020	31.12.2021	31.12.2020	31.03.2021	31.12.2021	31.12.2020	31.12.2021	31.12.2020	31.03.2021
	UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	AUDITED
Total Income from Operations (net)	19,690.67	13,069.06	51,824.75	37,366.44	48,319.56	22,229.42	16,817.66	59,969.42	45,904.97	59,742.98
Profit before Tax & Exceptional item	3,366.80	3,043.73	9,748.24	7,711.17	9,118.67	3,473.33	3,708.77	10,130.56	8,754.55	10,412.70
Profit before Tax	3,641.31	3,043.73	10,022.75	7,711.17	9,118.67	(3,886.12)	3,708.77	2,771.11	8,754.55	10,412.70
Net Profit for the period	2,717.38	2,245.61	7,355.92	5,833.94	6,750.08	(4,853.10)	2,755.82	(34.04)	6,581.91	7,397.16
Total Comprehensive Income for the period	2,728.82	2,239.57	7,368.37	5,874.64	6,802.48	(4,771.15)	2,579.59	(10.77)	6,217.66	7,345.87
Equity Share Capital	1,036.78	1,031.47	1,036.78	1,031.47	1,031.47	1,036.78	1,031.47	1,036.78	1,031.47	1,031.47
Other Equity	82,059.84	73,307.27	82,059.84	73,307.27	74,533.27	79,511.26	78,557.84	79,511.26	78,557.84	79,793.88
Earnings Per Share (Not annualised)										
i. Basic (₹)	2.62	2.18	7.09	5.66	6.54	(4.83)	2.48	(0.44)	6.03	6.64
ii. Diluted (₹)	2.57	2.13	6.96	5.54	6.40	(4.74)	2.43	(0.43)	5.91	6.49

Note:

- (1) The above is an extract of the detailed format of the Standalone and Consolidated financial results for the Quarter and Nine Months ended Dec 31, 2021 and Annual Result for the Year ended March 31, 2021 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The figures for the quarter ended December 31, 2021 are the balancing figures between unaudited figures in respect of the nine months ended December 31, 2021 and the year to date published figures for the half year ended Sept 30, 2021.
- (2) The full format of the Standalone and Consolidated financial results for the Quarter and Nine months ended Dec 31, 2021 and Annual Result for the Year ended March 31, 2021 are available on the Stock Exchange websites- www.bseindia.com and www.nseindia.com and on the Company's website www.blissgvs.com.
- (3) The results have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act read with relevant rules issued there under.
- (4) In the current quarter, with respect to consolidated financials statements, exceptional items represent impairment of trade receivable pertaining to a wholly owned subsidiary Bliss GVS Clinic Health Care Pte Ltd, Singapore. The said subsidiary has been sold by the Company for a consideration of USD 3,75,000 vide agreement dated 25th Nov, 2021 and is derecognised in the current quarter, though the consideration is received on January 5, 2022 and the concerned shares were transferred on January 12, 2022.
- (5) In the current quarter, standalone financials statements includes exceptional item ₹ 274.51 Lakh on profit on sale of a wholly owned subsidiary namely, Bliss GVS Clinic Health Care Pte Ltd, Singapore.

For **BLISS GVS PHARMA LIMITED**

SD/-

GAGAN HARSH SHARMA
MANAGING DIRECTOR

Din No : 07939421

Place : Mumbai
Date : January 29, 2022



BLISS GVS PHARMA LIMITED

CIN No. - L24230MH1984PLC034771

Registered Office: 102, Hyde Park, Sakinaka Road, Andheri (East), Mumbai - 400 072.

• Tel: 022-42160000 • Fax: 022-28563930 • Email: info@blissgvs.com • Website: www.blissgvs.com

EXTRACT OF STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2021

(₹ in Lakhs)

Particulars	STANDALONE					CONSOLIDATED				
	QUARTER ENDED		NINE MONTHS ENDED		YEAR ENDED	QUARTER ENDED		NINE MONTHS ENDED		YEAR ENDED
	31.12.2021	31.12.2020	31.12.2021	31.12.2020	31.03.2021	31.12.2021	31.12.2020	31.12.2021	31.12.2020	31.03.2021
	UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	AUDITED
Total Income from Operations (net)	19,690.67	13,069.06	51,824.75	37,366.44	48,319.56	22,229.42	16,817.66	59,969.42	45,904.97	59,742.98
Profit before Tax & Exceptional item	3,366.80	3,043.73	9,748.24	7,711.17	9,118.67	3,473.33	3,708.77	10,130.56	8,754.55	10,412.70
Profit before Tax	3,641.31	3,043.73	10,022.75	7,711.17	9,118.67	(3,886.12)	3,708.77	2,771.11	8,754.55	10,412.70
Net Profit for the period	2,717.38	2,245.61	7,355.92	5,833.94	6,750.08	(4,853.10)	2,755.82	(34.04)	6,581.91	7,397.16
Total Comprehensive Income for the period	2,728.82	2,239.57	7,368.37	5,874.64	6,802.48	(4,771.15)	2,579.59	(10.77)	6,217.66	7,345.87
Equity Share Capital	1,036.78	1,031.47	1,036.78	1,031.47	1,031.47	1,036.78	1,031.47	1,036.78	1,031.47	1,031.47
Other Equity	82,059.84	73,307.27	82,059.84	73,307.27	74,533.27	79,511.26	78,557.84	79,511.26	78,557.84	79,793.88
Earnings Per Share (Not annualised)										
I. Basic (₹)	2.62	2.18	7.09	5.66	6.54	(4.83)	2.48	(0.44)	6.03	6.64
ii. Diluted (₹)	2.57	2.13	6.96	5.54	6.40	(4.74)	2.43	(0.43)	5.91	6.49

Note:

(1) The above is an extract of the detailed format of the Standalone and Consolidated financial results for the Quarter and Nine Months ended Dec 31, 2021 and Annual Result for the Year ended March 31, 2021 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The figures for the quarter ended December 31, 2021 are the balancing figures between unaudited figures in respect of the nine months ended December 31, 2021 and the year to date published figures for the half year ended Sept 30, 2021.

(2) The full format of the Standalone and Consolidated financial results for the Quarter and Nine months ended Dec 31, 2021 and Annual Result for the Year ended March 31, 2021 are available on the Stock Exchange websites- www.bseindia.com and www.nseindia.com and on the Company's website www.blissgvs.com.

(3) The results have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act read with relevant rules issued there under.

(4) In the current quarter, with respect to consolidated financials statements, exceptional items represent impairment of trade receivable pertaining to a wholly owned subsidiary Bliss GVS Clinic Health Care Pte Ltd, Singapore. The said subsidiary has been sold by the Company for a consideration of USD 3,75,000 vide agreement dated 25th Nov, 2021 and is derecognised in the current quarter, though the consideration is received on January 5, 2022 and the concerned shares were transferred on January 12, 2022.

(5) In the current quarter, standalone financials statements includes exceptional item ₹ 274.51 Lakh on profit on sale of a wholly owned subsidiary namely, Bliss GVS Clinic Health Care Pte Ltd, Singapore.

For **BLISS GVS PHARMA LIMITED**

SD/-

GAGAN HARSH SHARMA

MANAGING DIRECTOR

Din No : 07939421

Place : Mumbai

Date : January 29, 2022

१४ | मुंबई, सोमवार, ३१ जानेवारी २०२२

नवशक्ति



BLISS GVS PHARMA LIMITED

CIN No. - L24230MH1984PLC034771

Registered Office: 102, Hyde Park, Sakinaka Road, Andheri (East), Mumbai - 400 072.

• Tel: 022-42160000 • Fax: 022-28563930 • Email: info@blissgvs.com • Website: www.blissgvs.com

EXTRACT OF STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2021

(₹ in Lakhs)

Particulars	STANDALONE					CONSOLIDATED				
	QUARTER ENDED		NINE MONTHS ENDED		YEAR ENDED	QUARTER ENDED		NINE MONTHS ENDED		YEAR ENDED
	31.12.2021	31.12.2020	31.12.2021	31.12.2020	31.03.2021	31.12.2021	31.12.2020	31.12.2021	31.12.2020	31.03.2021
	UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	AUDITED
Total Income from Operations (net)	19,690.67	13,069.06	51,824.75	37,366.44	48,319.56	22,229.42	16,817.66	59,969.42	45,904.97	59,742.98
Profit before Tax & Exceptional item	3,366.80	3,043.73	9,748.24	7,711.17	9,118.67	3,473.33	3,708.77	10,130.56	8,754.55	10,412.70
Profit before Tax	3,641.31	3,043.73	10,022.75	7,711.17	9,118.67	(3,886.12)	3,708.77	2,771.11	8,754.55	10,412.70
Net Profit for the period	2,717.38	2,245.61	7,355.92	5,833.94	6,750.08	(4,853.10)	2,755.82	(34.04)	6,581.91	7,397.16
Total Comprehensive Income for the period	2,728.82	2,239.57	7,368.37	5,874.64	6,802.48	(4,771.15)	2,579.59	(10.77)	6,217.66	7,345.87
Equity Share Capital	1,036.78	1,031.47	1,036.78	1,031.47	1,031.47	1,036.78	1,031.47	1,036.78	1,031.47	1,031.47
Other Equity	82,059.84	73,307.27	82,059.84	73,307.27	74,533.27	79,511.26	78,557.84	79,511.26	78,557.84	79,793.88
Earnings Per Share (Not annualised)										
i. Basic (₹)	2.62	2.18	7.09	5.66	6.54	(4.83)	2.48	(0.44)	6.03	6.64
ii. Diluted (₹)	2.57	2.13	6.96	5.54	6.40	(4.74)	2.43	(0.43)	5.91	6.49

Note:

- The above is an extract of the detailed format of the Standalone and Consolidated financial results for the Quarter and Nine Months ended Dec 31, 2021 and Annual Result for the Year ended March 31, 2021 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The figures for the quarter ended December 31, 2021 are the balancing figures between unaudited figures in respect of the nine months ended December 31, 2021 and the year to date published figures for the half year ended Sept 30, 2021.
- The full format of the Standalone and Consolidated financial results for the Quarter and Nine months ended Dec 31, 2021 and Annual Result for the Year ended March 31, 2021 are available on the Stock Exchange websites- www.bseindia.com and www.nseindia.com and on the Company's website www.blissgvs.com.
- The results have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act read with relevant rules issued there under.
- In the current quarter, with respect to consolidated financials statements, exceptional items represent impairment of trade receivable pertaining to a wholly owned subsidiary Bliss GVS Clinic Health Care Pte Ltd, Singapore. The said subsidiary has been sold by the Company for a consideration of USD 3,75,000 vide agreement dated 25th Nov, 2021 and is derecognised in the current quarter though the consideration is received on January 5, 2022 and the concerned shares were transferred on January 12, 2022.
- In the current quarter, standalone financials statements includes exceptional item ₹ 274.51 Lakh on profit on sale of a wholly owned subsidiary namely, Bliss GVS Clinic Health Care Pte Ltd, Singapore.

For **BLISS GVS PHARMA LIMITED**

SD/-

GAGAN HARSH SHARMA

MANAGING DIRECTOR

Din No : 07939421

Place : Mumbai
Date : January 29, 2022



ब्लिस जीव्हीएस फार्मा लिमिटेड

CIN No. - L24230MH1984PLC034771

नोंदणीकृत कार्यालय : - १०२, हाइड पार्क, साकीनाका रोड, अंधेरी (पूर्व), मुंबई ४०००७२

• दूरध्वनी क्र: ०२२-४२१६०००० • फॅक्स: ०२२-२८५६३९३० • इमेल: info@blissgvs.com • वेबसाईट: info@blissgvs.com

डिसेंबर ३१, २०२१ रोजी संपलेल्या तिमाही आणि नऊमाहीचे अलेखापरीक्षित एकल आणि एकत्रित आर्थिक निकाल यांच्या कोष्टकांचा सारांश

(रू. लाखांमध्ये)

तपशील	एकल					एकत्रित				
	संपलेली तिमाही		संपलेली नऊमाही		वर्षसमाप्ती	संपलेली तिमाही		संपलेली नऊमाही		वर्षसमाप्ती
	३१.१२.२०२१	३१.१२.२०२०	३१.१२.२०२१	३१.१२.२०२०	३१.०३.२०२१	३१.१२.२०२१	३१.१२.२०२०	३१.१२.२०२०	३१.१२.२०२०	३१.०३.२०२१
	अलेखापरीक्षित	अलेखापरीक्षित	अलेखापरीक्षित	अलेखापरीक्षित	लेखापरीक्षित	अलेखापरीक्षित	अलेखापरीक्षित	अलेखापरीक्षित	अलेखापरीक्षित	लेखापरीक्षित
ऑपरेशन्समधूनचे एकूण उत्पन्न (निव्वळ)	१९,६९०.६७	१३,०६९.०६	५१,८२४.७५	३७,३६६.४४	४८,३१९.५६	२२,२२९.४२	१६,८१७.६६	५९,९६९.४२	४५,९०४.९७	५९,७४२.९८
करापूर्वीचा नफा आणि अपवादात्मक वस्तू	३,३६६.८०	३,०४३.७३	९,७४८.२४	७,७११.१७	९,११८.६७	३,४७३.३३	३,७०८.७७	१०,१३०.५६	८,७५४.५५	१०,४१२.७०
करापूर्वीचा नफा	३,६४१.३१	३,०४३.७३	१०,०२२.७५	७,७११.१७	९,११८.६७	(३,८८६.१२)	३,७०८.७७	२,७७१.११	८,७५४.५५	१०,४१२.७०
कालावधीसाठीचे निव्वळ नफा	२,७१७.३८	२,२४५.६१	७,३५५.९२	५,८३३.९४	६,७५०.०८	(४,८५३.१०)	२,७५५.८२	(३४.०४)	६,५८९.९१	७,३९७.१६
कालावधीसाठीचे सर्वसमावेशक उत्पन्न	२,७२८.८२	२,२३९.५७	७,३६८.७०	५,८७४.६४	६,८०२.४८	(४,७७१.१५)	२,५७९.५९	(१०.७७)	६,२९७.६६	७,३४५.८७
इक्विटी समभाग भांडवल	१,०३६.७८	१,०३९.४७	१,०३६.७८	१,०३९.४७	१,०३९.४७	१,०३६.७८	१,०३९.४७	१,०३६.७८	१,०३९.४७	१,०३९.४७
इतर इक्विटी	८२,०५९.८४	७३,३०७.२७	८२,०५९.८४	७३,३०७.२७	७४,५३३.२७	७९,५११.२६	७८,५५७.८४	७९,५११.२६	७८,५५७.८४	७९,७९३.८८
समभाग उत्पन्न (वार्षिक नाही)										
I मूलभूत (₹)	२.६२	२.१८	७.०९	५.६६	६.५४	(४.८३)	२.४८	(०.४४)	६.०३	६.६४
ii. प्रवाही (डायल्यूटेड) (₹)	२.५७	२.१३	६.९६	५.५४	६.४०	(४.७४)	२.४३	(०.४३)	५.९१	६.४९

नोंद:

१. डिसेंबर ३१, २०२१ रोजी संपलेल्या तिमाही आणि नऊमाहीचे अलेखापरीक्षित एकल आणि एकत्रित आर्थिक निष्कर्ष यांच्या सविस्तर कोष्टकांचा वरील सारांश आणि मार्च ३१, २०२१ रोजी संपलेल्या आर्थिक वर्षाचा निकाल हे स्टॉक एक्सचेंजेमध्ये सेबी नियम २०१५च्या नियम ३३(लिरटिंग बंधने आणि जाहीर करण्याच्या आवश्यकता) यानुसार फाईल करण्यात आलेले आहेत. डिसेंबर ३१, २०२१ रोजी संपलेल्या तिमाहीचे आकडे हे डिसेंबर, ३१, २०२१ रोजी संपलेल्या नऊमाहीचे आणि सप्टेंबर ३०, २०२१ रोजी संपलेल्या अर्धवर्षाचे आजरोजी प्रकाशित आकडे यामधील समतोल साधणारे आकडे आहेत.

२. डिसेंबर ३१, २०२१ रोजी संपलेल्या तिमाही आणि नऊमाहीचे आणि मार्च ३१, २०२१ रोजी संपलेल्या वर्षाचे वार्षिक निकाल हे स्टॉक एक्सचेंजच्या वेबसाईट्स www.bseindia.com आणि www.nseindia.com आणि तसेच कंपनीची वेबसाईट www.blissgvs.com येथे उपलब्ध आहेत.

३. निकाल कंपनी कायद्याच्या कलम १३३ सोबत संबंधित नियम यानुसारच्या भारतीय अकाउंटिंग प्रमाण (Ind AS) अन्वये तयार करण्यात आले आहेत.

४. चालू तिमाहीमध्ये, एकत्रित आर्थिक विधानांच्या संदर्भाने, अपवादात्मक बाबी संपूर्ण मालकीची उपकंपनी ब्लिस जीव्हीएस क्लिनिक हेल्थ केअर पीटीई लिमिटेड, सिगापूरची संबंधित प्राप्य व्यापाराचा क्षय दर्शवतात. उक्त उपकंपनीची कंपनीद्वारे युएनडी ३,७५,००० प्रतिफलाने २५ नोव्हेंबर, २०२१ दिनांकित कराराद्वारे विक्री करण्यात आली आहे आणि चालू तिमाहीमध्ये मान्यता रद्द करण्यात आली आहे, तरी प्रतिफल दिनांक ५ जानेवारी, २०२२ मध्ये प्राप्त झाले आहे आणि संबंधित भाग दिनांक १२ जानेवारी, २०२२ रोजी हस्तांतरित करण्यात आले आहेत.

५. चालू तिमाहीमध्ये, एकल आर्थिक विधानांमध्ये म्हणजेच ब्लिस जीव्हीएस क्लिनिक हेल्थ केअर पीटीई लिमिटेड, सिगापूर या उपकंपनीच्या विक्रीतून आलेला रु. २७४.५१ लाख नफा ही अपवादात्मक बाब समाविष्ट आहे.

ब्लिस जीव्हीएस फार्मा लिमिटेड करिता

स्वक्षरी

गगन हर्ष शर्मा

व्यवस्थापकीय संचालक

डीआयएन क्र. ०७९३९४२१

स्थळ: मुंबई

दिनांक: २९ जानेवारी, २०२२